O
SPRO icon

OrbiMed’s Spero Therapeutics SPRO Stock Holding History

OrbiMed’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-131,653
Closed -$1.27M – 159
2019
Q4 		$1.27M Sell
131,653
-9,056
-6% -$97.7K 0.02% 127
2019
Q3 		$1.49M Sell
140,709
-366,762
-72% -$3.86M 0.03% 111
2019
Q2 		$5.84M Hold
507,471
– – 0.09% 106
2019
Q1 		$6.5M Buy
+507,471
New +$5.38M 0.1% 101

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

OrbiMed's SPRO Position: Q1 2020 in Review

OrbiMed sold out of Spero Therapeutics (SPRO) in Q1 2020, closing a stake of 131,653 shares — an estimated $1.27M sold.

OrbiMed first reported a position in SPRO in Q1 2019 and held it in 4 quarters. The position peaked at $6.5M in Q1 2019. 60 funds tracked by Wall St. Rank hold SPRO as of Q1 2020.

  • OrbiMed reported no remaining Spero Therapeutics position as of Q1 2020 after selling out during the quarter.
  • OrbiMed sold 131,653 Spero Therapeutics shares in Q1 2020, an estimated $1.27M.
  • OrbiMed first reported a position in Spero Therapeutics in Q1 2019 and held it in 4 quarters.
  • OrbiMed's Spero Therapeutics position peaked at $6.5M in Q1 2019.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2020.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.